Bank Julius Baer & Co
DNLI icon

Bank Julius Baer & Co’s Denali Therapeutics DNLI Stock Holding History

Bank Julius Baer & Co’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-500
Closed -$29K – 836
2021
Q1 		$29K Buy
+500
New +$33.5K ﹤0.01% 722

Other funds holding DNLI

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Bank Julius Baer & Co's DNLI Position: Q2 2021 in Review

Bank Julius Baer & Co sold out of Denali Therapeutics (DNLI) in Q2 2021, closing a stake of 500 shares — an estimated $29K sold.

Bank Julius Baer & Co first reported a position in DNLI in Q1 2021 and held it in 1 quarter. The position peaked at $29K in Q1 2021. 210 funds tracked by Wall St. Rank hold DNLI as of Q2 2021.

  • Bank Julius Baer & Co reported no remaining Denali Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Bank Julius Baer & Co sold 500 Denali Therapeutics shares in Q2 2021, an estimated $29K.
  • Bank Julius Baer & Co first reported a position in Denali Therapeutics in Q1 2021 and held it in 1 quarter.
  • Bank Julius Baer & Co's Denali Therapeutics position peaked at $29K in Q1 2021.
  • 210 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2021.

Based on Bank Julius Baer & Co's 13F filing for Q2 2021, filed 23 Jul 2021.